Skip to main content
SpringerLink
Log in

PAI-1 und t-PA bei Patienten mit Thrombozytosen im Rahmen von chronischen myeloproliferativen Erkrankungen

  • Conference paper
26. Hämophilie-Symposion 1995

  • 30 Accesses

Zusammenfassung

Bei Patienten mit Thrombozytosen infolge von chronischen myeloproliferativen Erkrankung (CMPE), insbesondere bei Patienten mit essentieller Thrombozythämie (ETZ), Osteomyelofibrose (OMF) und Polycythaemia rubra vera (PRV), stellen hämorrhagische und thromboembolische Episoden typische Manifestationen dar, ohne daß gesagt werden kann, ob und welche Komplikationen sich im Einzelfall einstellen [8,9,15,22,23,27,28].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  1. Alessi MC, Juhan-Vague I, Declerck PJ, Collen D (1991) Molecular forms of Plasminogen activator inhibitor-1 (PAI-1) and tissue-type Plasminogen activator (t-PA) in human plasma. Thromb Res 62:275–285

    Article  PubMed  CAS  Google Scholar 

  2. Bazaan M, Tamponi G, Stella S, Schinco PC, Pannocchia A, Pileri A (1993) Fibrinolytic imbalance in Essential Thrombocythemia: role of platelets. Haemostasis 23:138–44

    Google Scholar 

  3. Bellucci S, Ignatova E, Jaillet N, Boffa MC (1993) Platelet hyperactivation in patients with Essential Thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of Plasma Thrombomodulin, Protein S, PAI-1, t-PA und vWF. Thromb Haemost 70,5:736–742

    CAS  Google Scholar 

  4. Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR (1988) Plasminogen activator inhibitor (PAI-i) in plasma and platelets. Br J Haematol 70:327–333

    Article  PubMed  CAS  Google Scholar 

  5. Bridges AB, McLaren M, Scott NA, Pringle TH, McNeill GP, Belch JJF (1993) Circadian Variation of tissue Plasminogen activator and its inhibitor, von Willebrand factor antigen, and prostacyclin stimulating factor in men with ischaemic heart disease. Br Heart J 69:121–124

    Article  PubMed  CAS  Google Scholar 

  6. Cancelas JA, Garcia Avello A, Garcia Frade LJ (1994) High plasma levels of Plasminogen activator inhibitor 1 (PAI-i) in polycythemia vera and essential thrombocythemia are associated with thrombosis. Thromb Res 75:513–520

    Article  PubMed  CAS  Google Scholar 

  7. Cohen AM, Gelvan A, Kadouri A, Creter D, Djaldetti M (1990) Tissue Plasminogen Activator levels in different types of Polycythemia. Eur J Haematol 45:48–51

    Article  PubMed  CAS  Google Scholar 

  8. Colombi M, Radaelli F, Zocchi L, Maiolo AT (1991) Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer 67:2926–2930

    CAS  Google Scholar 

  9. Cortelazzo S, Viero P, Finazzi G, D’Emilio A, Rodeghiero F, Barbui T (1990) Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 8:556–562

    PubMed  CAS  Google Scholar 

  10. Craveri A, Tornaghi G, Ranieri R, Paganardi L (1990) Relations between overweight, thrombophilia and cardiovascular risk. Ann Ital Med Int 5:31–33

    PubMed  CAS  Google Scholar 

  11. Dawson S, Henney A (1992) The status of PAI-i as a risk factor for arterial and thrombotic disease: a review. Atherosclerosis 95:105–117

    Article  PubMed  CAS  Google Scholar 

  12. Declerck PJ, Alessi MC, Verstreken M, Kruithof EKO, Juhan-Vague I, Collen D (1988) Measurement of Plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 71:220–225

    PubMed  CAS  Google Scholar 

  13. Fenaux P, Simon M, Caulier T, Lai JL, Goudemand J, Bauters F (1990) Clinical course of essential thrombocythemia in 147 cases. Cancer 66:549–556

    Article  PubMed  CAS  Google Scholar 

  14. Friedenberg WR, Roberts RC, David DE (1992) Relationship of thrombohemorrhagic complications to endothelial cell function in patients with chronic myeloproliferative disorders. Am J Hematol 40:283–289

    Article  PubMed  CAS  Google Scholar 

  15. Griesshammer M, Seifried E, Heimpel H (1993) Essentielle Thrombozythämie. Klinische Bedeutung, Diagnostik und Therapie. Dtsch Med Wochenschr 118:1412–1417

    Article  PubMed  CAS  Google Scholar 

  16. Hashimoto Y, Kobayashi A, Yamazaki N, Sugawara Y, Takada Y, Takada A (1987) Relationship between age and plasma t-PA, PA-Inhibitor and PA activity. Thromb Res 46,5:625–633

    Article  PubMed  CAS  Google Scholar 

  17. Koh S, Yuen R, Viegas O, Chue S, Ng B, Sen D, Ratnam S (1991) Plasminogen Activators t-PA, u-PA and its Inhibitor (PAI) in normal males and females. Thromb Haemost 66/5:581–585

    Google Scholar 

  18. Krishnamuturi C, Tang DB, Barr CF, Alving BM (1988) Plasminogen Activator and Plasminogen Activator Inhibitor activities in a reference population. Am J Clin Pathol 89:747–752

    Google Scholar 

  19. Kruithof EK, Gudinchet A, Bachmann F (1988) Plasminogen Activator Inhibitor 1 and Plasminogen Activator Inhibitor 2 in various disease states. Thromb Haemost 59,1:7–12

    PubMed  CAS  Google Scholar 

  20. Lanir N, Brenner B, Tatarsky I (1992) Abnormalities of fibrinolytic parameters in patients with myeloproliferative diseases. Fibrinolysis 6:183–186

    Article  Google Scholar 

  21. Lee MH, Vosburgh E, Anderson K, McDonagh J (1993) Deficiency of plasma Plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding. Blood 81:2357–2362

    PubMed  CAS  Google Scholar 

  22. Mitus AJ, Schafer AI (1990) Thrombocytosis and thrombocythemia. Hematol Oncol Clin North Am 4:157–178

    PubMed  CAS  Google Scholar 

  23. Randi ML, Stocco F, Rossi C, Tison T, Girolami A (1991) Thrombosis and hemorrhage in thrombocytosis: evaluation of a large cohort of patients (357 cases). J Med 22:213–223

    PubMed  CAS  Google Scholar 

  24. Simpson AJ, Booth NA, Moore NR, Bennett B (1990) The platelet and plasma pools of Plasminogen activator inhibitor (PAI-1) vary independently in disease. Br J Haematol 75:543–548

    Article  PubMed  CAS  Google Scholar 

  25. Sloan IG, Firkin BG (1989) Impaired fibrinolysis in patients with thrombotic or haemostatic defects. Thromb Res 55:559–567

    Article  PubMed  CAS  Google Scholar 

  26. Tanimura LK, Weddell JA, McKown CG, Shapiro AD, Mulherin J (1994) Oral management of a patient with a plasminogen activator inhibitor (PAI-1) deficiency: case report. Pediatr Dent 16:133–135

    PubMed  CAS  Google Scholar 

  27. VanGenderen PJ, Michiels JJ (1994) Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia. Presse Med 23:73–77 (Abstract)

    PubMed  Google Scholar 

  28. Wehmeier A, Daum I, Jamin H, Schneider W (1991) Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. Ann Hematol 63:101–106

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. M. Schiemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Depka Prondzinski
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Stoll
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. Scharrer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Schiemann, M., Depka Prondzinski, M., Stoll, H., Scharrer, I. (1997). PAI-1 und t-PA bei Patienten mit Thrombozytosen im Rahmen von chronischen myeloproliferativen Erkrankungen. In: 26. Hämophilie-Symposion 1995. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60418-8_51

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-60418-8_51

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-61101-1

  • Online ISBN: 978-3-642-60418-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation